Arnasi

About Arnasi

Arnasi Group, a company spun out from the Massachusetts Institute of Technology (MIT), is directing its proprietary surface technology towards the biomedical and consumer packaged goods sectors. The firm originated as LiquiGlide in 2012, founded by Professor Kripa Varanasi and his then-graduate student David Smith, who is the current CTO. Their journey began in Varanasi's lab with the invention of a liquid-impregnated surface technology that allows products to slide easily from containers, a project initially backed by the MIT Energy Initiative and the Deshpande Center. This technology gained early recognition, leading to the company's formation and major deals with consumer goods companies, including a notable application in no-stick toothpaste for Colgate.

In late 2023, the company rebranded to Arnasi Group, signaling a strategic pivot from primarily a technology licensor to a developer of its own branded products. This new direction is led by Chairman and CEO Dan Salain, a veteran with 28 years of experience in the global pharmaceutical and CPG industries. The business model is now focused on leveraging its core technology to create and market products that address specific patient and consumer needs, particularly where enhanced user experience can be a significant differentiator. Arnasi generates revenue through the sale of these new products.

The company's initial product launch under the new strategy is Revel, an FDA-registered deodorizing lubricant for ostomy pouches. This product is designed to prevent clogging and simplify the cleaning process for the up to 1 million people in the U.S. who rely on these devices. Unlike other options, a single, pocket-sized dose of Revel is effective for an entire day, offering a non-water-based solution that improves drainage and convenience for users. Looking forward, Arnasi plans to apply its surface technology to a pipeline of medical products aimed at preventing biofilm and bacterial infections on implants and catheters, as well as developing solutions for individuals with cystic fibrosis.